Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
Massachusetts China Partnership Official Delegation visitors includedrepresentatives from Massachusetts life science industry and academia such asJoshua Schafer Boger, Chief Executive Officer of Vertex Pharmaceuticals, andJack Martin Wilson, President of University of Massachusetts.
Advertisement
Massachusetts is the U.S.'s epicenter for biotechnology, with over 300biopharmaceutical companies located in the state. With the intellectualresources of leading universities and healthcare institutions, biotechnologyhas become one of the most important industries in Massachusetts.
During the meeting between the honorable guests and the management team ofthe company, Dr. Ge Li, Chairman and Chief Executive Officer of WuXiPharmaTech, gave Governor Patrick a brief introduction of the company andhoped for more collaboration opportunities between the two parties forcontinued expansion of the biopharmaceutical industry.
"I am here to encourage the collaboration that WuXi PharmaTech has withMassachusetts companies such as Vertex, and with enterprises everywhere thathave the interest and ability to contribute to the future of healing,"commented Governor Patrick in his address. "This collaboration has benefitsfor both Massachusetts and China, and for the future of health care all overthe world. Working together, we will be stronger and more successful than weever could be working apart."
The Governor added, "As in the United States, China's population is agingand life science is helping to alleviate suffering and improve quality of lifefor so many. By helping to find new treatments and cures while loweringhealth care system cost, life science gives us the opportunity to do wellwhile doing good."
Commenting on the delegation's visit, Joshua Boger, Vertex PharmaceuticalsCEO and official delegation member said, "Through our over four years ofcooperation, WuXi PharmaTech has become a trusted and important partner forour business. A trip to WuXi PharmaTech is a must-do for any life sciencescompany visiting China."
As China's leading provider of pharmaceutical R&D outsourcing services,WuXi PharmaTech helps more than 20 Massachusetts pharmaceutical and biotechcompanies accelerate their drug discovery from idea to market.
"We are much honored to host Governor Patrick and his delegation. WuXiPharmaTech has cultivated deep relationships with the financial and lifescience industries in Massachusetts. With the trust from our customers andsupport from the government, we look forward to serving more pharma andbiotech companies in Massachusetts," commented Dr. Ge Li, Chairman and ChiefExecutive Officer of WuXi PharmaTech.
About WuXi PharmaTech
Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-basedpharmaceutical and biotechnology R&D outsourcing company. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceuticaland biotechnology companies with a broad and integrated portfolio oflaboratory and research manufacturing services throughout the drug discoveryand development process. WuXi PharmaTech's services are designed to assistits global partners in shortening the cycle and lowering the cost of drugdiscovery and development by providing cost-effective and efficientoutsourcing solutions that save its customers both time and money. Itsoperations are grouped into two segments: laboratory services, consisting ofdiscovery chemistry, service biology, analytica
